American Journal of Ophthalmology
Volume 146, Issue 6 , Pages 799-801 , December 2008

Education in the Ophthalmic Discipline of Uveitis

  • Justine R. Smith

      Affiliations

    • Casey Eye Institute, Oregon Health & Science University, Portland, Oregon
    • Corresponding Author InformationInquiries to Justine R. Smith, Biomedical Research Building, L467AD, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239
    • ,
  • Douglas A. Jabs

      Affiliations

    • Department of Ophthalmology, Mount Sinai School of Medicine, New York, New York
    • ,
  • Daniel J. Briceland

      Affiliations

    • American Academy of Ophthalmology, San Francisco, California
    • ,
  • Gary N. Holland

      Affiliations

    • Ocular Inflammatory Disease Center, Jules Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California

,Accepted 15 September 2008.

References 

  1. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111:491–500discussion 500
  2. Darrell RW, Wagener HP, Kurland LT. Epidemiology of uveitis (Incidence and prevalence in a small urban community). Arch Ophthalmol. 1962;68:502–514
  3. Suhler EB, Lloyd MJ, Choi D, et al. Incidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest. Am J Ophthalmol. 2008;146:890–896
  4. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80:844–848
  5. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513
  6. Thorne JE, Jabs DA, Peters GB, Hair D, Dunn JP, Kempen JH. Birdshot retinochoroidopathy: ocular complications and visual impairment. Am J Ophthalmol. 2005;140:45–51
  7. Thorne JE, Wittenberg S, Jabs DA, et al. Multifocal choroiditis with panuveitis incidence of ocular complications and of loss of visual acuity. Ophthalmology. 2006;113:2310–2316
  8. Nussenblatt RB. Proctor Lecture (Experimental autoimmune uveitis: mechanisms of disease and clinical therapeutic indications). Invest Ophthalmol Vis Sci. 1991;32:3131–3141
  9. Smith JR, Hart PH, Williams KA. Basic pathogenic mechanisms operating in experimental models of acute anterior uveitis. Immunol Cell Biol. 1998;76:497–512
  10. Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol. 1993;115:763–769
  11. Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2008;146:837–844
  12. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol. 2008;146:845–850
  13. Myles ME, Neumann DM, Hill JM. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev. 2005;57:2063–2079
  14. Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112:1916.e1–1916.e7
  15. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113:1020–1027
  16. Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56:307–318
  17. Keltner JL, Fine SL, Abrams GW, Mondino B. Subspecialty fellowships: standardizing and enhancing the educational experience. Ophthalmology. 2007;114:628.e1–628.e3
  18. McCannel CA, Holland GN, Helm CJ, Cornell PJ, Winston JV, Rimmer TG. Causes of uveitis in the general practice of ophthalmology (UCLA Community-Based Uveitis Study Group). Am J Ophthalmol. 1996;121:35–46
  19. Moorthy RS, Davis J, Foster CS. Intraoular Inflammation and Uveitis. San Francisco, California: American Academy of Ophthalmology; 2007;
  20. Lum F, Jones JL, Holland GN, Liesegang TJ. Survey of ophthalmologists about ocular toxoplasmosis. Am J Ophthalmol. 2005;140:724–726
  21. Delair E, Monnet D, Grabar S, et al. Respective roles of acquired and congenital infections in presumed ocular toxoplasmosis. Am J Ophthalmol. 2008;146:851–855
  22. Dodds EM, Holland GN, Stanford MR, et al. Intraocular inflammation associated with ocular toxoplasmosis: relationships at initial examination. Am J Ophthalmol. 2008;146:856–865
  23. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data (Results of the First International Workshop). Am J Ophthalmol. 2005;140:509–516
  24. Holland GN, Lewis KG. An update on current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 2002;134:102–114

PII: S0002-9394(08)00745-9

doi: 10.1016/j.ajo.2008.09.018

American Journal of Ophthalmology
Volume 146, Issue 6 , Pages 799-801 , December 2008

Article Tools